DEC1 expression in 1p-aberrant oligodendroglial neoplasms

Histology and Histopathology

Volumn 20, Issue 4, 2005, Pages 1173-1177

  Presusser, M ^a   Birner, P ^b   Ambros, I M ^c   Ambros, P F ^c   Budka, H ^a   Harris, A L ^d   Hainfellner, Johannes A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Hypoxia; Immunohistochemistry; Oligodendroglioma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; DIFFERENTIATED EMBRYOCHONDROCYTE EXPRESSED PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ANTIBODY LABELING; ARTICLE; ASTROCYTOMA; BRAIN HYPOXIA; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; ENDOTHELIUM CELL; FEMALE; GLIA CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; OLIGODENDROGLIOMA; PROTEIN EXPRESSION; TUMOR CELL; TUMOR NECROSIS;

ADULT; ANOXIA; BIOLOGICAL MARKERS; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; NECROSIS; OLIGODENDROGLIOMA; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 27144486154     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Acker T. and Plate K.H. (2004). Hypoxia and hypoxia inducible factors (HIF) as important regulators of tumor physiology. Cancer Treat. Res. 117, 219-48.
2. Ambros P.F., Ambros I.M., Kerbl R., Luegmayr A., Rumpler S., Ladenstein R., Amann G., Kovar H., Horcher E., De Bernardi B., Michon J. and Gadner H. (2001). Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas. Med. Pediatr. Oncol. 36, 1-4.
3. Birner P., Gatterbauer B., Oberhuber G., Schindl M., Rossler K., Prodinger A., Budka H. and Hainfellner J.A. (2001). Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92, 165-171.
4. Birner P., Preusser M., Gelpi E., Berger J., Gatterbauer B., Ambros I.M., Ambros P.F., Acker T., Plate K.H., Harris A.L. and Hainfellner J.A. (2004). Expression of hypoxia-related tissue factors correlates with diminished survival of adjuvantly treated patients with chromosome 1p aberrant oligodendroglial neoplasms and therapeutic implications. Clin. Cancer Res. 10, 6567-6571.
5. Bredel M., Gatterbauer B., Birner P., Haberler C., Strobel T., Budka H., Rossler K. and Hainfellner J.A. (2002). Expression of DNA topoisomerase IIalpha in oligodendroglioma. Anticancer Res. 22, 1301-1304.
6. Breitschopf H., Suchanek G., Gould R.M., Colman D.R. and Lassmann H. (1992). In situ hybridization with digoxigenin-labeled probes: sensitive and reliable detection method applied to myelinating rat brain. Acta Neuropathol. 84, 581-587.
7. Cairncross J.G., Ueki K., Zlatescu M.C., Lisle D.K., Finkelstein D.M., Hammond R.R., Silver J.S., Stark P.C., Macdonald D.R., Ino Y., Ramsay D.A. and Louis D.N. (1998). Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 90, 1473-1479.
8. Chakrabarti J., Turley H., Campo L., Han C., Harris A.L., Gatter K.C. and Fox S.B. (2004). The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers. Br. J. Cancer 91, 954-958.
9. Chan A.S., Leung S.Y., Wong M.P., Yuen S.T., Cheung N., Fan Y.W. and Chung L.P. (1998). Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am. J. Surg. Pathol. 22, 816-826.
10. Gelpi E., Ambros I.M., Birner P., Luegmayr A., Drlicek M., Fischer I., Kleinert R., Maier H., Huemer M., Gatterbauer B., Anton J., Rossler K., Budka H., Ambros P.F. and Hainfellner J.A. (2003). Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens. Mod. Pathol. 16, 708-715.
11. Giatromanolaki A., Koukourakis M.I., Sivridis E., Turley H., Wykoff C.C., Gatter K.C. and Harris A.L. (2003). DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. J. Pathol. 200, 222-228.
12. Ivanova A.V., Ivanov S.V., Danilkovitch-Miagkova A. and Lerman M.I. (2001). Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway. J. Biol. Chem. 276, 15306-15315.
13. Kaanders J.H., Bussink J. and van der Kogel A.J. (2002). ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol. 3, 728-737.
14. Kleihues P. and Cavenee W. (2000). World Health Organisation classification of tumours: Pathology and genetics of tumours of the nervous system. Lyon, IARC Press.
15. Knisely J.P. and Rockwell S. (2002). Importance of hypoxia in the biology and treatment of brain tumors. Neuroimaging Clin. N. Am. 12, 525-536.
16. Miyazaki K., Kawamoto T., Tanimoto K., Nishiyama M., Honda H. and Kato Y. (2002). Identification of functional hypoxia response elements in the promoter region of the DEC1 and DEC2 genes. J. Biol. Chem. 277, 47014-47021.
17. Plate K.H., Breier G., Weich H.A. and Risau W. (1992). Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845-848.
18. Smits A. (2002). Low-grade gliomas: clinical and pathobiological aspects. Histol. Histopathol. 17, 253-60.
19. Turley H., Wykoff C.C., Troup S., Watson P.H., Gatter K.C. and Harris A.L. (2004). The hypoxia-regulated transcription factor DEC1 (Stra13, SHARP-2) and its expression in human tissues and tumours. J. Pathol. 203, 808-13.
20. Uehara M., Sano K., Ikeda H., Sekine J., Irie A., Yokota T., Tobita T., Ohba S. and Inokuchi T. (2004). Expression of vascular endothelial growth factor and prognosis of oral squamous cell carcinoma. Oral Oncol. 40, 321-325.
21. Vinores S.A., Youssri A.I., Luna J.D., Chen Y.S., Bhargave S., Vinores M.A., Schoenfeld C. L., Peng B., Chan C.C., LaRochelle W., Green W.R. and Campochiaro P.A. (1997). Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol. Histopathol. 12, 99-109.
22. Vordermark D. and Brown J.M. (2003). Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther. Onkol. 179, 801-811.